Total Valuation
JW Pharmaceutical Corporation has a market cap or net worth of ₩622.19B. The enterprise value is $603.48K.
Market Cap₩622.19B
Enterprise Value$603.48K
Share Statistics
JW Pharmaceutical Corporation has 23,285,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,285,930
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
JW Pharmaceutical Corporation’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 14.08%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)14.08%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee728.20M
Profits Per Employee54.79M
Employee Count1,064
Asset Turnover1.28
Inventory Turnover3.79
Valuation Ratios
The current PE Ratio of JW Pharmaceutical Corporation is 6.3. JW Pharmaceutical Corporation’s PEG ratio is -2.42.
PE Ratio6.3
PS Ratio0.79
PB Ratio1.67
Price to Fair Value1.67
Price to FCF7.27
Price to Operating Cash Flow4.66
PEG Ratio-2.42
Income Statement
In the last 12 months, JW Pharmaceutical Corporation had revenue of 774.80B and earned 61.69B in profits. Earnings per share was 2.53K.
Revenue774.80B
Gross Profit359.31B
Operating Income87.88B
Pretax Income88.84B
Net Income61.69B
EBITDA106.62B
Earnings Per Share (EPS)2.53K
Cash Flow
In the last 12 months, operating cash flow was 134.48B and capital expenditures -20.28B, giving a free cash flow of 114.20B billion.
Operating Cash Flow134.48B
Free Cash Flow114.20B
Free Cash Flow per Share4.90K
Dividends & Yields
JW Pharmaceutical Corporation pays an annual dividend of $650, resulting in a dividend yield of ―
Dividend Per Share$650
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.40
52-Week Price Change25.01%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
JW Pharmaceutical Corporation upcoming earnings date is Nov 18, 2026, TBA (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
JW Pharmaceutical Corporation as a current ratio of 1.42, with Debt / Equity ratio of 17.50%
Current Ratio1.42
Quick Ratio0.89
Debt to Market Cap0.05
Net Debt to EBITDA0.14
Interest Coverage Ratio19.86
Taxes
In the past 12 months, JW Pharmaceutical Corporation has paid 27.32B in taxes.
Income Tax27.32B
Effective Tax Rate0.31
Enterprise Valuation
JW Pharmaceutical Corporation EV to EBITDA ratio is 5.92, with an EV/FCF ratio of 7.46.
EV to Sales0.81
EV to EBITDA5.92
EV to Free Cash Flow7.46
EV to Operating Cash Flow6.55
Balance Sheet
JW Pharmaceutical Corporation has ₩59.65B in cash and marketable securities with ₩71.75B in debt, giving a net cash position of -₩12.10B billion.
Cash & Marketable Securities₩59.65B
Total Debt₩71.75B
Net Cash-₩12.10B
Net Cash Per Share-₩519.65
Tangible Book Value Per Share₩12.63K
Margins
Gross margin is 47.32%, with operating margin of 11.34%, and net profit margin of 7.96%.
Gross Margin47.32%
Operating Margin11.34%
Pretax Margin11.47%
Net Profit Margin7.96%
EBITDA Margin13.76%
EBIT Margin11.34%
Analyst Forecast
The average price target for JW Pharmaceutical Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast10.50%
EPS Growth Forecast96.29%